Jessica Hope Roark

Array ( [id] => 16962925 [patent_doc_number] => 20210214424 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-15 [patent_title] => NOVEL LEUCINE-RICH REPEAT NEURONAL PROTEIN 1 (LRRN1) ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/054994 [patent_app_country] => US [patent_app_date] => 2019-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8045 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17054994 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19120020 [patent_doc_number] => 11963981 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-04-23 [patent_title] => Chimeric antigen receptor [patent_app_type] => utility [patent_app_number] => 17/054670 [patent_app_country] => US [patent_app_date] => 2019-05-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 14948 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17054670 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14715665 [patent_doc_number] => 20190248896 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-15 [patent_title] => ANTI-NKG2A ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/397271 [patent_app_country] => US [patent_app_date] => 2019-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30669 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16397271 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16321305 [patent_doc_number] => 10781261 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-09-22 [patent_title] => Subcutaneous formulations of anti-CD38 antibodies and their uses [patent_app_type] => utility [patent_app_number] => 16/380994 [patent_app_country] => US [patent_app_date] => 2019-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 24989 [patent_no_of_claims] => 37 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16380994 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15589773 [patent_doc_number] => 20200071421 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-05 [patent_title] => BISPECIFIC ANTIBODY [patent_app_type] => utility [patent_app_number] => 16/377712 [patent_app_country] => US [patent_app_date] => 2019-04-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19322 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 104 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16377712 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15020933 [patent_doc_number] => 20190321471 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-24 [patent_title] => COMPOSITIONS COMPRISING ANTI-CD38 ANTIBODIES AND CARFILZOMIB [patent_app_type] => utility [patent_app_number] => 16/375693 [patent_app_country] => US [patent_app_date] => 2019-04-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8764 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16375693 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15035553 [patent_doc_number] => 20190328781 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-31 [patent_title] => MANUFACTURING METHODS FOR CELL-BASED THERAPEUTIC COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 16/375696 [patent_app_country] => US [patent_app_date] => 2019-04-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6746 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16375696 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14581391 [patent_doc_number] => 20190218304 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-18 [patent_title] => POTENTIATING THE EFFECT OF ATP RELEASE [patent_app_type] => utility [patent_app_number] => 16/370789 [patent_app_country] => US [patent_app_date] => 2019-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32506 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -36 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16370789 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15454501 [patent_doc_number] => 20200040075 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-06 [patent_title] => V-C-FC-V-C ANTIBODY [patent_app_type] => utility [patent_app_number] => 16/352213 [patent_app_country] => US [patent_app_date] => 2019-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21629 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16352213 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14896983 [patent_doc_number] => 20190292257 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-26 [patent_title] => METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR - EXPRESSING CELLS [patent_app_type] => utility [patent_app_number] => 16/291651 [patent_app_country] => US [patent_app_date] => 2019-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 57162 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16291651 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14467881 [patent_doc_number] => 20190185583 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-20 [patent_title] => ANTI-CEA ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/288587 [patent_app_country] => US [patent_app_date] => 2019-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31439 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16288587 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14715657 [patent_doc_number] => 20190248892 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-15 [patent_title] => THERAPEUTIC CD47 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/288957 [patent_app_country] => US [patent_app_date] => 2019-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12393 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16288957 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17922845 [patent_doc_number] => 11466078 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-10-11 [patent_title] => Heterodimeric immunoglobulins [patent_app_type] => utility [patent_app_number] => 16/267758 [patent_app_country] => US [patent_app_date] => 2019-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 18 [patent_no_of_words] => 43608 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16267758 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15293619 [patent_doc_number] => 20190389945 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-26 [patent_title] => IL-1 Binding Proteins [patent_app_type] => utility [patent_app_number] => 16/265614 [patent_app_country] => US [patent_app_date] => 2019-02-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 81478 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16265614 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16686771 [patent_doc_number] => 20210069246 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-11 [patent_title] => COMBINATION THERAPY USING ADOPTIVE CELL THERAPY AND CHECKPOINT INHIBITOR [patent_app_type] => utility [patent_app_number] => 16/965287 [patent_app_country] => US [patent_app_date] => 2019-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 104394 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -123 [patent_words_short_claim] => 137 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16965287 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14338949 [patent_doc_number] => 20190151447 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-23 [patent_title] => COMBINATION OF LENALIDOMIDE AND POLYPEPTIDE CONSTRUCT, AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/263611 [patent_app_country] => US [patent_app_date] => 2019-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14198 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16263611 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19666152 [patent_doc_number] => 12178872 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-31 [patent_title] => Regulatory T cell expressing a chimeric antigen receptor [patent_app_type] => utility [patent_app_number] => 16/962755 [patent_app_country] => US [patent_app_date] => 2019-01-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 13891 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 124 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16962755 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17496537 [patent_doc_number] => 11285221 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-03-29 [patent_title] => Treating myelomas [patent_app_type] => utility [patent_app_number] => 16/247253 [patent_app_country] => US [patent_app_date] => 2019-01-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8260 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16247253 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14897019 [patent_doc_number] => 20190292275 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-26 [patent_title] => SEQUENCING-DIRECTED SELECTION OF TUMOR THERANOSTICS [patent_app_type] => utility [patent_app_number] => 16/245382 [patent_app_country] => US [patent_app_date] => 2019-01-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38727 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16245382 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18518528 [patent_doc_number] => 11708409 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-07-25 [patent_title] => Antibody or antigen-binding fragment thereof that specifically recognizes B cell malignancies, chimeric antigen receptor comprising same, and uses thereof [patent_app_type] => utility [patent_app_number] => 16/956807 [patent_app_country] => US [patent_app_date] => 2018-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 13933 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 124 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16956807 [rel_patent_id] =>[rel_patent_doc_number] =>)